Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Phase I Trials

15 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Treatment

VICCPHI1436

08/18/2014

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Treatment

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Treatment

VICCPHI1435

07/31/2014

First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects with Advanced Stage Solid Tumors

Treatment

VICCPHI1387

05/28/2014

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients with Locally Advanced or Metastatic Cancers with Mutant KRAS

Treatment

VICCMD13112

05/19/2014

Phase IB Study of MK-3475 in Subjects with Select Advanced Solid Tumors

Treatment

VICCPHI1375

05/16/2014

Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies BVD-523-01

Treatment

Breast
Colon
Lung
Ovarian
Pancreatic
Prostate
Rectal

VICCPHI1394

04/17/2014

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Treatment

VICCPHI1364

03/07/2014

A Phase Ib, Open-Label Study of Oral BGJ398 in Combination with Oral BYL719 in Adult Patients with Select Advanced Solid Tumors

Treatment

VICCPHI1342

02/11/2014

A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors

Treatment

VICCPHI1255

09/28/2013

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Treatment

Prostate

VICCURO1260

03/19/2013

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Treatment

Breast

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Treatment

Pancreatic

VICCGI1173

07/31/2012

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma

Treatment

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Treatment

GIST

VICCPHI0958

02/05/2010

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology